| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Kappa/Lamba Light Chains, Free with Ratio, Serum : 11234
Test CodeFLTCHN : 11234
Alias/See Also
Immunoglobulin Free Light Chains
CPT Codes
83521x2
Includes
This test includes Kappa Light Chain, Free, Lambda Light Chain, Free, and the Kappa/Lambda Light Chains, Free Ratio
Instructions
Plain red top tube or Serum Separator Tube (SST).
Transport Container
Centrifuge the Serum Separator Tube (SST); if plain red top, centrifuge and aliquot serum (2.0 mL, minimum 1.0 mL) into a standard transport tube.
Transport Temperature
Room temperature.
Specimen Stability
Room temperature: 72 hours; Refrigerated: 21 days; Frozen: 30 days
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Gross hemolysis, gross lipemia, microbial contamination, heavy visible particulate
Methodology
Immunoturbidimetric
Setup Schedule
Monday - Friday
Report Available
1-4 days
Reference Range
Kappa Light Chain, Free, Serum 3.3-19.4 mg/L
Lambda Light Chain, Free, Serum 5.7-26.3 mg/L
Kappa/Lambda Light Chains Free with Ratio, Serum 0.26-1.65
Lambda Light Chain, Free, Serum 5.7-26.3 mg/L
Kappa/Lambda Light Chains Free with Ratio, Serum 0.26-1.65
Clinical Significance
This test measures the amount of kappa and lambda free light
chains (FLCs) in the blood and calculates the kappa to
lambda ratio. It is used to assist in the diagnosis of
plasma cell disorders, including multiple myeloma, primary
amyloidosis, monoclonal gammopathy of unknown significance
(MGUS), Waldenstrom's macroglobulinemia, and related
disorders. It is also used to monitor disease activity and
treatment.
Kappa and lambda light chains link with heavy chains to form
immunoglobulins. In healthy individuals, most serum light
chains are bound to heavy chains. However, excess
plasma-cell proliferation associated with plasma-cell
disorders can cause an excess of circulating FLCs and
increase or decrease the K/L ratio.
This test is intended for patients clinically suspected of
having hematologic disease, based on certain symptoms and
medical conditions. These include bone pain, bone fractures,
normocytic anemia, kidney disease, and recurrent infections
suggestive of an underlying plasma-cell disorder.
Note that blood samples that are grossly hemolyzed or
lipemic or contain high levels of circulating immune
complexes (CICs) should not be tested, because of the
unpredictable degree of nonspecific scatter these sample
types may generate.
chains (FLCs) in the blood and calculates the kappa to
lambda ratio. It is used to assist in the diagnosis of
plasma cell disorders, including multiple myeloma, primary
amyloidosis, monoclonal gammopathy of unknown significance
(MGUS), Waldenstrom's macroglobulinemia, and related
disorders. It is also used to monitor disease activity and
treatment.
Kappa and lambda light chains link with heavy chains to form
immunoglobulins. In healthy individuals, most serum light
chains are bound to heavy chains. However, excess
plasma-cell proliferation associated with plasma-cell
disorders can cause an excess of circulating FLCs and
increase or decrease the K/L ratio.
This test is intended for patients clinically suspected of
having hematologic disease, based on certain symptoms and
medical conditions. These include bone pain, bone fractures,
normocytic anemia, kidney disease, and recurrent infections
suggestive of an underlying plasma-cell disorder.
Note that blood samples that are grossly hemolyzed or
lipemic or contain high levels of circulating immune
complexes (CICs) should not be tested, because of the
unpredictable degree of nonspecific scatter these sample
types may generate.
Performing Laboratory
med fusion
